Comparative Clinical Efficacy and Safety of the Proposed Biosimilar ABP 710 With Infliximab Reference Product in Patients With Rheumatoid Arthritis
Arthritis Research & Therapy
doi 10.1186/s13075-020-2142-1
Full Text
Abstract
Available in
Date
March 26, 2020
Authors
Publisher
Springer Science and Business Media LLC